Title / AuthorYear
EASL recommendations on treatment of hepatitis C 2016.
European Association for The Study of The Liver
Journal of hepatology 66 (1), 153
2017
EASL recommendations on treatment of hepatitis C 2018
European Association for The Study of The Liver
Journal of hepatology 69 (2), 461-511
2018
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals
F Conti, F Buonfiglioli, A Scuteri, C Crespi, L Bolondi, P Caraceni, ...
Journal of hepatology 65 (4), 727-733
2016
Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review
O Falade-Nwulia, C Suarez-Cuervo, DR Nelson, MW Fried, JB Segal, ...
Annals of internal medicine 166 (9), 637-648
2017
Cost-of-illness studies: concepts, scopes, and methods
C Jo
Clinical and molecular hepatology 20 (4), 327
2014
Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study
LS Belli, M Berenguer, PA Cortesi, M Strazzabosco, SR Rockenschaub, ...
Journal of hepatology 65 (3), 524-531
2016
Hepatitis C virus infection
MP Manns, M Buti, ED Gane, JM Pawlotsky, H Razavi, N Terrault, ...
Nature reviews Disease primers 3 (1), 1-19
2017
EASL recommendations on treatment of hepatitis C 2018
JM Pawlotsky, F Negro, A Aghemo, M Berenguer, O Dalgard, G Dusheiko, ...
Journal of hepatology 69 (2), 461-511
2018
The American Society of Transplantation Consensus Conference on the use of hepatitis C viremic donors in solid organ transplantation
J Levitsky, RN Formica, RD Bloom, M Charlton, M Curry, J Friedewald, ...
American Journal of Transplantation 17 (11), 2790-2802
2017
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
TM Welzel, J Petersen, K Herzer, P Ferenci, M Gschwantler, ...
Gut 65 (11), 1861-1870
2016
Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension
M Mandorfer, K Kozbial, P Schwabl, C Freissmuth, R Schwarzer, R Stern, ...
Journal of hepatology 65 (4), 692-699
2016
Reduction in liver transplant wait‐listing in the era of direct‐acting antiviral therapy
JA Flemming, WR Kim, CL Brosgart, NA Terrault
Hepatology 65 (3), 804-812
2017
Treatment with ledipasvir–sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial
M Colombo, A Aghemo, H Liu, J Zhang, H Dvory-Sobol, R Hyland, C Yun, ...
Annals of internal medicine 166 (2), 109-117
2017
Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection
Clinical Infectious Diseases 67 (10), 1477-1492
2018
Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: results from the HCV‐TARGET study
V Saxena, V Khungar, EC Verna, J Levitsky, RS Brown Jr, MA Hassan, ...
Hepatology 66 (4), 1090-1101
2017
Reversion of disease manifestations after HCV eradication
AJ van der Meer, M Berenguer
Journal of hepatology 65 (1), S95-S108
2016
Hepatocellular carcinoma and direct acting antiviral treatments: controversy after the revolution
JC Nault, M Colombo
Journal of Hepatology 65 (4), 663-665
2016
Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection
AIHCVG Panel
Clinical infectious diseases: an official publication of the Infectious …
2018
Regression of fibrosis and portal hypertension in HCV‐associated cirrhosis and sustained virologic response after interferon‐free antiviral therapy
V Knop, D Hoppe, T Welzel, J Vermehren, E Herrmann, A Vermehren, ...
Journal of viral hepatitis 23 (12), 994-1002
2016
Clinical applications of transient elastography
KS Jung, SU Kim
Clinical and molecular hepatology 18 (2), 163
2012
1 - 20
Dates and citation counts are estimated and are determined automatically by a computer program.